China’s Sinovac secures $500 million in funding for Covid-19 vaccine development

In a statement on its website, the company said it expects to be able to manufacture 300 million vaccine doses annually, and that it aims to complete construction of a second production facility by the end of 2020 to increase annual Covid-19 vaccine production capacity to 600 million doses.
Sinovac said the investor is Sino Biopharmaceutical Ltd.(Reuters)
Sinovac said the investor is Sino Biopharmaceutical Ltd.(Reuters)
Updated on Dec 07, 2020 06:23 AM IST
Copy Link
Shanghai | ByReuters| Posted by Susmita Pakrasi

China’s Sinovac Biotech said on Monday that it had secured approximately $500 million in funding for Covid-19 vaccine development.

In a statement on its website, the company said it expects to be able to manufacture 300 million vaccine doses annually, and that it aims to complete construction of a second production facility by the end of 2020 to increase annual Covid-19 vaccine production capacity to 600 million doses.

Sinovac said the investor is Sino Biopharmaceutical Ltd.

SHARE THIS ARTICLE ON
Close Story
SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, January 20, 2022